Category Archives: Nano Medicine

Many of us have traumatic memories of going to the doctor to get the flu shot or childhood vaccines when we were younger. This feeling isnt uncommon as 17 per cent of the population suers from anxiety or needle phobia. Your child self wasnt being irrational eitherneedles have proven to be a pain for the medical industry as well.

Although the transdermal patch has gained popularity over the years as an innovative way to deliver medicine into ones system, jet injectors have also made waves due to their benefits in rapid administration, improved dosing accuracy, faster response rates, better diffusion into tissues, and reduced sharps waste, according to a report by Grand View Research.

For those who dread needles, a solution is on the way, and its becoming a much more pervasive method of delivering drugs, without the associated fear. As needles become outdated, Inolife R&D is working on a method to implement needle-free injections with its pipeline of prototypes for the next generation of technology.

The point of needle-free

Inolife is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. The company commercializes FDA-cleared and CE approved needle-free injection systems catering to a wide range of applications. Being CE approved is particularly impressive as it means that they are conform to all health, safety and environmental concerns in Europe, which are among the strictest in the world. They have also long been focused on research and development, having acquired Dutch company, European Pharmagroup, to tap into their existing global knowledge base.

Michael Wright, CEO and President, Inolife R&D.

The need for needle-free injectors goes far beyond visits to the doctor for vaccines, and the potential market benefit is massive. Some of these applications include potential use for diabetes, dental anesthesia, vaccinations, autoimmune disease, erectile dysfunction, cancer treatments, growth hormones, cosmetics (for injections of Hyaluronic Acid and similar products), and veterinary applications.

Diabetes is especially one of the fastest-growing diseases around the globeit is estimated that 374 millionpeople are at increased risk of developing type 2 diabetes.Dr. Ricordi, M.D., and Inolifes Advisory Board member, works closely with the company on improving solutions for diabetics.

He explains his involvement, "It is my professional life mission to help people who have diabetes. Inolife's synergistic mission makes us excellent strategic partners. Their technology allows diabetes patients to inject their medication without needles, with the objective of increasing care plan compliance and improving overall outcomes.

I look forward to working with Inolife to positively impact the world through novel drug delivery system development.

Inolife is bringing to market injectors that can allow for at-home insulin injections, entirely without the usage of a needle. As Michael Wright, CEO and President of Inolife notes, Cross-contamination when handling needles is a major concern globally.

Our devices have no needles and do not perforate the skin while injecting and therefore, the risk of a needlestick injury is eliminated and when done, it does not require the same costly process for disposal as a biohazard. It can be discarded or eventually recycled.

Moreover, needles are dangerous and complicated to dispose of, providing a serious biohazard after use. Many viruses can live up to 48 hours on a needle, and special biohazard bins are needed for disposal. With no needle, these concerns vanish.

Not just in science fiction

So how exactly do you inject without a needle? While each product in the Inolife family is slightly different, they all work on the same principle. Regular needles work by puncturing the skin to deliver a pool of liquid into the tissue, but the Inolife needle-free injectors deliver the fluid just under the epidermis in the subcutaneous layer by a fine high-speed jet stream.

Because there is no needle penetrating the skin, theres a smaller chance of infection. Its also much more efficient, as the medicine spreads out evenly, rather than creating a pooling effectso in the case of being used for anesthetics, you wont get that uncomfortable situation where a dentist has to inject you multiple times in multiple places. It also has a much faster uptake. The dermal layer is what protects our body, and our body thus reacts fastest to materials spread into the first line of defense.

Inolife also carries Ino 100 which is a self-injectable that can be used for up to 50 injections per nozzle. It harbours the following characteristics as well:

The COVID-19 pandemic truly proves the importance that remote medicine is going to have in the future.

Partnerships for success

Interest in Inolife has already led to a series of partnerships, joint ventures and endorsements, as the company is searching to make a difference on a global scale. It was joint ventures with pharmaceutical companies that helped develop the key nano-powder described above. These partnerships will allow for a global supply chain to patients across the globe when larger-scale production begins.

Many of those interested in Inolife are major players in global health. For example, Pharmajet, works closely with the World Health Organization (WHO) in adapting needle-free injectors for use in vaccines. The pharmaceutical industry in general has expressed a keen interest in the technology, as it anticipates a future demand for more user-friendly devices and whats more user friendly than dropping needles?

Governments have also taken note. Israel expressed its approval of the technology, and former Mexican President and Legal Representative of Centro Fox, Vincente Fox, was so interested that he became an advisor of the company.

The full press release can be viewed here.

He explains, To Centro Fox and myself, personally, this represents a great opportunity to accomplish our plan of removing the risk of needle stick injuries and cross contamination for care givers, as well as reduce anxiety for patients. Our main driver is to think of patient comfort at the system-level as well as improve home care compliancy. We want to fundamentally change how physicians and patients interact.

He adds, Now that Inolife Sciences has shown a viable and proven business model, we are moving to partner with pharmaceutical companies to enhance their therapeutic applications and compliancy by using Inolifes current technologies. We also look into the very near future and see the positive impact the Inolife nanoparticle powder injection technology could have on the entire injection marketwe can expect a few more partnerships this year and, in the years, to come.

Inolife is also looking to partnerships to perhaps expand beyond the medicines it already envisions. Studies in collaboration with McGill University are looking to develop a cannabidiol injectable to compete with other drugs for chronic pain and inflammation.

Plans for the Future

Wright is organizing private fundraising and is getting ready to take the company into public listing, which is a crucial milestone that investors should keep an eye peeled for. While a lot of focus has been on R&D and partnerships, Wright has expressed his interest in a scalable business, selling not just the injectors but the supply of the disposable syringes and further developed nano-powder injectables.

Clinical testing is also running at full steam on many of their planned products. Inolife was founded with the intention to positively impact peoples wellbeing and it is only warming up to the task. The invention of the hypodermic needle was once a medical breakthrough. One day, however, it may end up in a museum as an outdated relic, only serving as a story to scare our children about how we used to take our medicine.

Learn more about Inolife by visiting their website here.

See how the companys technology works by watching their YouTube video below.

For more investor-related information please email Chris Brown, Global Capital Markets or Michael Wright, CEO, Inolife Sciences.

See more here:
Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca

Released by MarketsandResearch.biz, Global Healthcare Nanotechnology Market 2020 by Company, Regions, Type and Application, Forecast to 2026 profoundly explores an overarching research study which talks about the current market scenario. The report explains the overall global Healthcare Nanotechnology market journey in the previous five years along with the prophecy made by the experts in the industry. The report attributes product innovation, and technological advancements boosting market development in the near future. A comprehensive study of key market dynamics and current trends, along with relevant market sectors and sub-sectors is offered. The report incorporates important factors such as market opportunities, risk, benefit, opportunity, loss, and profit.

Market Overview:

Data associated with the market on the products, strategies and market share of leading companies of this market are mentioned. Detailed understandings into ongoing industry trends, trend prediction, and growth drivers are offered in the report. Additionally, potential market risks, obstacles, threats, and uncertainties are also determined in the report. Market segments examined in the report include major types, applications, regions, and end-users. This research study features the data about the global Healthcare Nanotechnology market share held by every region with potential growth prospects on the basis of the regional analysis. The research document serves accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/41102

Competitive rivalry scenario for the global Healthcare Nanotechnology market: Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International,

The study broadly exemplifies, the regional hierarchy of this market, while categorizing the same into: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other

On the basis of application, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Anticancer, CNS Product, Anti-infective, Other,

Drivers & Challenges:

The market report delivers information about the driving factors affecting the revenue scale of this global Healthcare Nanotechnology industry as well as their influence on the commercialization graph of this business sphere. The research study incorporates the latest trends building up the market in conjunction with the challenges that this business vertical will face over the forecast duration. Additionally, it encompasses the obstacles that this industry will be characterized by, in the forecast timeframe.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/41102/global-healthcare-nanotechnology-market-2020-by-company-regions-type-and-application-forecast-to-2026

Report Answers Following Questions:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read more from the original source:
Global Healthcare Nanotechnology Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2026 - Cole of Duty

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the publication of its universal registration document for the financial year ended December 31, 2019. This document has been approved by the French financial market authority (Autorit des marchs financiers or AMF) on May 12, 2020 under the number R.20-010.

This document is available on Nanobiotixs website on https://www.nanobiotix.com/regulated-information/ and on the AMF website on (www.amf-france.org).

The 2019 universal registration document includes:

- the 2019 financial annual report,- the management report, including the information and the report on corporate governance,- The reports from the Companys statutory auditors and information related to their fees, and- The required information in relation to the Companys share buy-back program

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France as well as, through an affiliate, in Cambridge, MA in the U.S.

DisclaimerThis press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix approved by the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-018 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

See the original post here:
Nanobiotix: Publication of the 2019 Universal Registration Document - Business Wire

The recently published market study by GLOBAL MARKETERS.BIZ highlights the current trends that are expected to influence the dynamics of the Healthcare Nanotechnology market in the upcoming years. The report introspect the supply chain, cost structure, and recent developments pertaining to the Healthcare Nanotechnology market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Healthcare Nanotechnology market are thoroughly studied in the presented market study.

Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.globalmarketers.biz/report/medicine/global-healthcare-nanotechnology-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130533#request_sample

Leading Players Are :

AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmith & NephewLeadiant BiosciencesKyowa Hakko KirinShireIpsenEndo International

Reasons to Trust Our Business Insights

Proven track record of delivering high-quality and insightful market studies

Data collected from credible sources including product managers, sales representatives, marketing executives, and more

Providing accurate insights for over ten industrial verticals

Swift delivery of reports with COVID-19 impact without any delays

Up-to-date market research and analytical tools used to curate market reports

Critical Data in the Healthcare Nanotechnology Market Report

Company share analysis and competition landscape

Recent trends and notable developments in the Healthcare Nanotechnology market space

Growth projections of each market segment and sub-segment during the forecast period

COVID-19 impact on the global Healthcare Nanotechnology market

Recent innovations, product launches, and technological advances relevant to the Healthcare Nanotechnology market

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Healthcare Nanotechnology market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Healthcare Nanotechnology and offers a fair assessment of the supply-demand ratio of each application including:

Market Taxonomy

By Type

NanomedicineNano Medical DevicesNano DiagnosisOther

By Application

AnticancerCNS ProductAnti-infectiveOther

Enquire Here For Customization:

https://www.globalmarketers.biz/inquiry/customization/130533

By Region

North America

Latin America

Europe

China

Japan

SEA and Other APAC

MEA

Get Table of Contents with Charts, Figures & Tables https://www.globalmarketers.biz/report/medicine/global-healthcare-nanotechnology-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130533#table_of_contents

The report resolves the following doubts related to the Healthcare Nanotechnology market:

1. Who are the leading market players operating in the current Healthcare Nanotechnology market landscape?

2. Which region is expected to dominate the Healthcare Nanotechnology market in terms of market share and size during the forecast period?

3. What are the various factors that are likely to contribute to the growth of the Healthcare Nanotechnology market in the upcoming years?

4. What is the most impactful marketing strategy adopted by players in the Healthcare Nanotechnology market?

5. What is the projected CAGR growth of application 1 during the forecast period?

See the rest here:
Global Healthcare Nanotechnology Market Trends, Applications, Competitive Strategies and Future Outlook 2025. - Cole of Duty

Global Nanotechnology Drug Delivery Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ 98.2 Bn by 2026, at a XX% CAGR of around during a forecast period.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Various novel technologies for developing effective drug delivery systems came into existence among which nanotechnology platforms for achieving targeted drug delivery are gaining prominence nowadays. Research in the medical field includes the development of drug nanoparticles, polymeric and inorganic biodegradable nano-carriers for drug delivery, and surface engineering of carrier molecules.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39035

The report contains a detailed list of factors that will drive and restrain the growth of the Nanotechnology Drug Delivery Market. Such as, rapidly expanding areas of research and development to develop novel nano-medicine are expected to drive the nanotechnology drug delivery market growth in the future. Additionally, one of the major factors assisting market growth is the growing prevalence of infectious diseases and cancer, developing nanotechnology research, and increasing demand for novel drug delivery systems. However, high cost coupled with stringent regulatory scenario hinders the market growth to some extent.

Nanoparticles are expected to account for the largest XX% market share by 2026. The segment dominated the market as key nanoparticles like gold nanoparticles, dendrimers, and fullerenes are used in pharmaceutical drug delivery.The report offers a brief analysis of the major regions in the global nanotechnology drug delivery market, namely, APAC, Europe, North America, South America, and the Middle East & Africa. North America dominated the nanotechnology drug delivery market in 2018, because of high medical reimbursement facilities, and technological advancement. The APAC is projected to have the fastest growth, owing to a rapidly increasing population, an increase in consumer awareness, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing economies such as China, and India in this region.

Nanotechnology drug delivery market report gives a competitive analysis of the individual standing of the companies against the global landscape of the medical industry. The forecast also provides the estimated trends in demand for the global market and their impact on the sizes of these companies to help the reader curate profitable business strategies. Such as Pfizer, Inc., AstraZeneca and Amgen signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the upcoming future.

The objective of the report is to present comprehensive analysis of Global Nanotechnology Drug Delivery Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Nanotechnology Drug Delivery Market dynamics, structure by analyzing the market segments, and project the Global Nanotechnology Drug Delivery Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Nanotechnology Drug Delivery Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/39035

Scope of the Global Nanotechnology Drug Delivery Market

Global Nanotechnology Drug Delivery Market, by Technology

Nanocrystals Nanoparticleso Dendrimerso Gold Nanoparticleso Dendrimerso Fullereneso Others Liposomes Micelles Nanotubes OthersGlobal Nanotechnology Drug Delivery Market, by Application

Neurology Oncology Cardiovascular/Physiology Anti-inflammatory/Immunology Anti-infective OthersGlobal Nanotechnology Drug Delivery Market, by Region

North America Asia Pacific Europe Middle East & Africa South AmericaKey players operating in the Global Nanotechnology Drug Delivery Market

Johnson & Johnson Merck & Co Roche Bayer Novartis Pharmaceuticals Pfizer AstraZeneca Amgen Celgene Corporation Angiotech Pharmaceuticals Capsulution Pharma AlphaRx Inc. Calando Pharmaceuticals Copernicus Therapeutics Elan Corporation Nanotherapeutics PAR Pharmaceutica Taiwan Liposome Co. AbbVie, Inc Amgen, Inc

MAJOR TOC OF THE REPORT

Chapter One: Nanotechnology Drug Delivery Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanotechnology Drug Delivery Market Competition, by Players

Chapter Four: Global Nanotechnology Drug Delivery Market Size by Regions

Chapter Five: North America Nanotechnology Drug Delivery Revenue by Countries

Chapter Six: Europe Nanotechnology Drug Delivery Revenue by Countries

Chapter Seven: Asia-Pacific Nanotechnology Drug Delivery Revenue by Countries

Chapter Eight: South America Nanotechnology Drug Delivery Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanotechnology Drug Delivery by Countries

Chapter Ten: Global Nanotechnology Drug Delivery Market Segment by Type

Chapter Eleven: Global Nanotechnology Drug Delivery Market Segment by Application

Chapter Twelve: Global Nanotechnology Drug Delivery Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanotechnology Drug Delivery Market Report at:https://www.maximizemarketresearch.com/market-report/global-nanotechnology-drug-delivery-market/39035/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View post:
Global Nanotechnology Drug Delivery Market: Industry Analysis and Forecast (2019-2026): By Technology, Application and Region - Azizsalon News

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14305

Company Profiles

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14305

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care.

A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer.

Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities.

This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.

Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Opioids MarketOpioids Market Segmented By Morphine, Codeine, Fentanyl, Meperidine, Methadone Product in Analgesia, Cough Suppression, Diarrhea Suppression.For More Information

Non Infectious Macular Edema Treatment MarketNon-infectious Macular Edema Treatment Market Segmented By Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics Drug with Non-infectious Uveitic Macular Edema, Diabetic Macular Edema, Retinal Vein Occlusion with Macular Edema Indication by Oral, Parenteral, Topical Route of Administration.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

Originally posted here:
Research Report Explores The Triple Negative Breast Cancer Treatment Market Will Be Valued At US$ 720 Mn By 2026 - Lake Shore Gazette